Majority of T-cell targets not on COVID-19 Spike protein, study finds
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
List view / Grid view
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
This article outlines the ideal scientific research that should be conducted to design a prophylactic to combat COVID-19.
Researchers experimenting on macaques reveal they were protected against reinfection up to a month after the initial exposure to SARS-CoV-2.
Researchers have suggested that the MMR live attenuated vaccine could be used to provide non-specific protection to patients against sepsis associated with COVID-19.
Researchers have analysed the SARS-CoV-2 proteome to reveal seven promising immunodominant epitopes that could aid in the development of a COVID-19 vaccine.
Researchers used computational tools to identify regions of the SARS-CoV-2 virus that could potentially provide a safe and long-term immune response.
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
Researchers demonstrate that a subpopulation of circulating white blood cells can act as an early indicator of vaccine efficacy, with potential implications for COVID-19 drug development.
Macaques were protected against SARS-CoV-2 infection both after an initial infection and vaccination with a prototype vaccine, researchers suggest humans could respond similarly.
A detailed analysis of the body's immune response to COVID-19 has revealed that it can recognise SARS-CoV-2 in many ways, meaning vaccines can be used to stop the spread of the virus.
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.